Pharmabiz6d
Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma
Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...
Pharm Exec6d
FDA Approves Pfizer’s Adcetris for Relapsed or Refractory Large B-Cell Lymphoma
Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...
Diffuse Large B-Cell Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug Adcetris and a tablet formulation of Roche’s R ...
Armed robbery in Revesby6d
FDA OKs Pfizer's ADCETRIS Combo for Relapsed Lymphoma
About ECHELON-3 ECHELON-3 is an ongoing, randomized, double-blind, multicenter Phase 3 study evaluating ADCETRIS plus lenalidomide and rituximab versus lenalidomide and rituximab plus placebo in adult ...
Yahoo Finance2d
Pfizer Inc. (PFE)
in combination with lenalidomide and a rituximab product for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma ...
Pfizer halts work on hemophilia gene therapy, Nikkei reports
Pfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the ...
pharmaphorum6d
Seattle, Takeda aim for first line Adcetris use
Takeda and Seattle Genetics are closing in on a new front-line use for their Adcetris in classical Hodgkin lymphoma after a successful late-stage trial. The positive results from the phase 3 ...
pharmaphorum6d
NICE backs NHS use of Takeda’s Adcetris for rare blood cancer
Takeda’s antibody-drug conjugate Adcetris can now be routinely available on the NHS to patients with a rare form of non-Hodgkin lymphoma (NHL), says NICE. The final draft guidance from the ...